                                                                                                                                          0                 1
                                                                             The CHMP confirmed eligibility to the centralised procedure on      09 June 2020
                                                                               The ETF recommended to start the rolling review procedure on 22 September 2020
The applicant submitted documentation as part of a rolling review on \nnon-clinical data to support the marketing authorisation application 30 September 2020
                                                                                                The procedure (Rolling Review 1) started on   01 October 2020
                                            The Rapporteur's first Assessment Report was circulated to all CHMP, \nPeer Reviewer and ETF on   15 October 2020
                                        The Rapporteurs circulated updated Joint Assessment reports to all \nCHMP, Peer Reviewer and ETF on   27 October 2020
                                                                                                              ETF discussions took place on   29 October 2020
                                                    Adoption of first Interim Opinion (Rolling Review 1) via 24 hour written \nprocedure on  06 November 2020